Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Zemuron, ORG 9426
Rocuronium bolus maintenance · 1 trial · 1 indication
Total dose from administration of intubating dose to reappearance of T3 (the third twitch of a Train of Four \[TOF\] stimulation) after the last maintenance bolus dose or discontinuation of Zemuron (rocuronium) infusion (Per protocol \[PP\] data set)
| Arm | Type | Description |
|---|---|---|
| Rocuronium bolus maintenance | EXPERIMENTAL | Rocuronium bolus maintenance |
| Rocuronium continuous infusion maintenance | EXPERIMENTAL | Rocuronium continuous infusion maintenance |
| Name | Type | Description |
|---|---|---|
| Rocuronium bolus maintenance | DRUG | Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation |
| rocuronium continuous infusion maintenance | DRUG | Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation |
Inclusion Criteria: * Male and female subjects from birth up to 17 years of age who are scheduled for surgery with an anticipated duration of anesthesia of about 2 hours or more requiring a maintenance muscle relaxation dose(s). Exclusion Criteria: * Subjects whose parent(s) or legal guardian(s) ...
Rocuronium bolus maintenance is used to sustain muscle relaxation during anesthesia. It is a small molecule neuromuscular blocking agent given as repeated bolus doses to maintain the paralysis established by an initial dose, supporting procedures such as intubation and surgery in pediatric and adolescent patients.
Rocuronium bolus maintenance targets nicotinic acetylcholine receptors at the neuromuscular junction, specifically the CHRNA1, CHRNG, CHRNB1, CHRND, and CHRNE subunits. It acts as an antagonist at these receptors, blocking acetylcholine signaling and producing skeletal muscle relaxation during anesthesia.
Rocuronium bolus maintenance is developed by Merck & Company, Inc., which trades under the ticker MRK. The product is associated with the brand name Zemuron.
Rocuronium bolus maintenance has been studied in Phase 3 clinical development. It is an investigational use of rocuronium bromide for maintaining neuromuscular blockade, and the Phase 3 trial evaluating dose requirements in pediatric and adolescent subjects has been completed.
Rocuronium bolus maintenance was evaluated in the Phase 3 trial NCT00124735, titled a study to determine the dose requirements of rocuronium bromide (Zemuron) in pediatric and adolescent subjects. That trial enrolled 149 participants, was randomized and controlled, and is now completed.
Yes. Rocuronium bolus maintenance refers to the bolus dosing of rocuronium bromide, which is marketed under the brand name Zemuron. The Phase 3 trial NCT00124735 used the Zemuron name when studying dose requirements in pediatric and adolescent subjects.